Quick Search:

uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-57564

Denton, C P; Avouac, J; Behrens, F; Furst, D E; Foeldvari, I; Humbert, M; Huscher, D; Kowal-Bielecka, O; Matucci-Cerinic, M; Nash, P; Opitz, C F; Pittrow, D; Rubin, L J; Seibold, J R; Distler, O (2011). Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed. Arthritis Research & Therapy, 13(3):114.

[img]
Preview
Published Version
PDF
144kB

Abstract

Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc). In clinical trials PAH-SSc has been grouped with other forms, including idiopathic PAH. The primary endpoint for most pivotal studies was improvement in exercise capacity. However, composite clinical endpoints that better reflect long-term outcome may be more meaningful. We discuss potential endpoints and consider why the same measures may not be appropriate for both idiopathic PAH and PAH-SSc due to inherent differences in clinical outcome and management strategies of these two forms of PAH. Failure to take this into account may compromise progress in managing PAH in SSc.

Item Type:Journal Article, not refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
DDC:610 Medicine & health
Language:English
Date:2011
Deposited On:29 Jan 2012 17:05
Last Modified:29 Dec 2013 08:05
Publisher:BioMed Central
ISSN:1478-6354
Publisher DOI:10.1186/ar3346
PubMed ID:21699746
Citations:Web of Science®. Times Cited: 1
Google Scholar™
Scopus®. Citation Count: 1

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page